Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo

Clinical Infectious Diseases

Volumn 63, Issue , 2016, Pages S88-S94

  Deshpande, Devyani ^a   Srivastava, Shashikant ^a   Nuermberger, Eric ^b   Pasipanodya, Jotam G ^a   Swaminathan, Soumya ^c   Gumbo, Tawanda ^a,d  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

additivity; Bliss independence; disseminated tuberculosis; exposure response surface; hollow fiber system model

Indexed keywords

ISONIAZID; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; CHILD; CHILDHOOD DISEASE; COMBINATION DRUG THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; HUMAN; MILIARY TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RATE CONSTANT; AGE; CELL LINE; COMPUTER SIMULATION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; THEORETICAL MODEL; TUBERCULOSIS;

AGE FACTORS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; CELL LINE; CHILD; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84994559571     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw473     Document Type: Article

References (43)

1. Jindani A, Doré CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167:1348-54.
2. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981; 1:171-4.
3. Lecoeur HF, Lagrange PH, Truffot-Pernot C, Gheorghiu M, Grosset J. Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin Exp Immunol 1989; 76:458-62.
4. Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother 2011; 55:1527-32.
5. Chigutsa E, Pasipanodya JG, Visser ME, et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 2015; 59:38-45.
6. Swaminathan S, Pasipanodya J, Ramachandran G, Srivastava S, Deshpande D, Gumbo T. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis 2016; 63(suppl 3):S63-74.
7. Almeida D, Nuermberger E, Tasneen R, et al. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 2009; 53:4178-84.
8. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992; 36:548-51.
9. Grosset J, Almeida D, Converse PJ, et al. Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci U S A 2012; 109:15001-5.
10. Datta M, Swaminathan S. Global aspects of tuberculosis in children. Paediatr Respir Rev 2001; 2:91-6.
11. Mandalakas AM, Starke JR. Current concepts of childhood tuberculosis. Semin Pediatr Infect Dis 2005; 16:93-104.
12. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N. The spectrum of disease in children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis 2006; 10:732-8.
13. Srivastava S, Pasipanodya JG, Ramachandran G, et al. A long-term co-perfused disseminated tuberculosis-3D liver hollow fiber model for both drug efficacy and hepatotoxicity in babies. EBioMedicine 2016; 6:126-38.
14. Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168:1342-5.
15. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653-7.
16. Pletz MW, De RA, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48:780-2.
17. Capitano B, Mattoes HM, Shore E, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 2004; 125:965-73.
18. Deshpande D, Srivastava S, Meek C, Leff R, Hall GS, Gumbo T. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother 2010; 54:2534-9.
19. Alffenaar JW, van Altena R, Bokkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009; 49:1080-2.
20. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58:693-6.
21. Malincarne L, Ghebregzabher M, Moretti MV, et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J Antimicrob Chemother 2006; 57:950-4.
22. Deshpande D, Srivastava S, Pasipanodya JG, et al. Linezolid for infants and toddlers with disseminated tuberculosis: first steps. Clin Infect Dis 2016; 63(suppl 3): S80-7.
23. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother 2003; 51(suppl 2):ii17-25.
24. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45:1843-6.
25. Traunmuller F, Schintler MV, Spendel S, et al. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents 2010; 36:84-6.
26. Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50:3971-6.
27. Yogev R, Damle B, Levy G, Nachman S. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J 2010; 29:827-30.
28. DePestel DD, Peloquin CA, Carver PL. Peritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitis. Pharmacotherapy 2003; 23:1322-6.
29. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190:1642-51.
30. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22:S153-7.
31. Thee S, Garcia-Prats AJ,DraperHR, et al. Pharmacokinetics and safety ofmoxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis 2015; 60:549-56.
32. Hiruy H, Rogers Z, Mbowane C, et al. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother 2015; 70:1115-23.
33. Bayer HealthCare. Safety, tolerability and pharmacokinetics of single dose intravenous moxifloxacin in pediatric patients, 2011. Available at: http://trialfinder. bayerscheringpharma.de/html/pdf/11826-Study-Synopsis-CTP.pdf. Accessed 18 July 2016.
34. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47:331-85.
35. MacSynergy II. Version 1.0. User's manual. Ann Arbor: University of Michigan, 1992.
36. Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol 1939; 26:585-615.
37. Chigutsa E, Patel K, Denti P, et al. A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother 2013; 57:789-95.
38. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208:1464-73.
39. Srivastava S, Sherman C, Meek C, Leff R, Gumbo T. Pharmacokinetic mismatch does not lead to emergence of isoniazid-or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemother 2011; 55:5085-9.
40. Zou L, Liu M, Wang Y, Lu J, Pang Y. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates. Tuberculosis (Edinb) 2015; 95:839-42.
41. Nachman S, Ahmed A, Amanullah F, et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis 2015; 15:711-20.
42. Srivastava S, Deshpande D, Pasipanodya J, et al. Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: Goldilocks. Clin Infect Dis 2016; 63(suppl 3):S102-9.
43. Deshpande D, Srivastava S, Nuermberger E, Pasipanodya J, Swaminathan S, Gumbo T. A faropenem, linezolid, and moxifloxacin regimen for both drugsusceptible and multidrug-resistant tuberculosis in children: FLAME path on the Milky Way. Clin Infect Dis 2016; 63(suppl 3):S95-101.